Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for their Omicron JN.1-adapted monovalent COVID-19 vaccine. The CHMP has recommended the approval of Comirnaty JN.1, the Omicron JN.1-adapted monovalent COVID- 19 vaccine, for active immunization against the COVID-19 virus in individuals aged six months and above. The decision was based on the recommendation from the World Heal ...